Loading...
Pfizer Q2 2025 Earnings Report
Pfizer reported strong second-quarter 2025 results, driven by strengthened commercial execution and continued progress in its R&D pipeline, leading to a raise in its 2025 Adjusted diluted EPS guidance.
Key Takeaways
Pfizer delivered a robust second quarter in 2025, with revenues reaching $14.7 billion, marking a 10% operational increase year-over-year. The company's reported diluted EPS was $0.51, while adjusted diluted EPS stood at $0.78, reflecting a 30% increase. This strong performance led Pfizer to reaffirm its full-year 2025 revenue guidance and raise its adjusted diluted EPS guidance, demonstrating confidence in its strategic execution and operational efficiency.
Second-quarter 2025 revenues increased by 10% operationally year-over-year, reaching $14.7 billion.
Reported diluted EPS for Q2 2025 was $0.51, and Adjusted diluted EPS was $0.78, a 30% increase from the prior year.
Pfizer reaffirmed its full-year 2025 revenue guidance and raised its Adjusted diluted EPS guidance by $0.10.
The company is on track to achieve approximately $7.2 billion in overall anticipated net cost savings from previously announced cost improvement initiatives by the end of 2027.
Revenue by Segment
Forward Guidance
Pfizer reaffirmed its full-year 2025 revenue guidance and raised its Adjusted diluted EPS guidance, reflecting strong year-to-date performance, confidence in its business, and progress with cost improvement initiatives.
Positive Outlook
- Reaffirmed full-year 2025 Revenue guidance in a range of $61.0 to $64.0 billion.
- Raised full-year 2025 Adjusted diluted EPS guidance by $0.10 to a range of $2.90 to $3.10.
- Updated Adjusted diluted EPS guidance considers strong year-to-date performance and continued business confidence.
- Favorable impact from foreign exchange and progress with ongoing cost improvement initiatives are factored into the raised EPS guidance.
- Improvement in the effective tax rate on Adjusted income to approximately 13.0% (previously 15.0%).
Challenges Ahead
- The raised Adjusted diluted EPS guidance absorbs a one-time impact of approximately $0.20 related to the 3SBio transaction.
- Guidance includes a one-time $1.35 billion Acquired In-Process R&D charge related to the licensing agreement with 3SBio, Inc. to be recorded in Q3 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...